Press Releases

Press Releases

The information contained in press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.


21 May, 2020

Incyte to Present at Upcoming Investor Conference

20 May, 2020

Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab

14 May, 2020

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings

14 May, 2020

MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL

06 May, 2020

Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with METex14

05 May, 2020

Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs

29 April, 2020

Incyte to Present at Upcoming Investor Conference

24 April, 2020

Incyte Appoints Christine Lennon as General Manager, Incyte Biosciences Canada

22 April, 2020

Incyte Announces Pivotal REACH2 Study Data Published in NEJM Highlight Superior Efficacy of Ruxolitinib (Jakafi®) versus Best Available Therapy in Patients with Acute Graft-Versus-Host Disease

17 April, 2020

FDA Approves Incyte’s Pemazyre™ (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma

of 1 2 3 4 Next page

For Media Inquiries

Catalina Loveman
Executive Director, Public Affairs

+1 302.498.6171 |

For Investor Relations

Michael Booth, D.Phil.
Divisional VP of Investor Relations and Corporate Responsibility

Phone: 302.498.5914


Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility

Phone: 302.498.6141


Christine Chiou
Senior Director, Investor Relations

Phone: 302.274.4773